Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026
- Interim Phase 3 findings will be presented in a prestigious late-breaking oral session at the leading meeting for kidney health professionals.
Covered in this story
Call it yourself
No calls on $HUMA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Humacyte Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.